• Je něco špatně v tomto záznamu ?

Proteomics of Mouse Heart Ventricles Reveals Mitochondria and Metabolism as Major Targets of a Post-Infarction Short-Acting GLP1Ra-Therapy

J. de Freitas Germano, A. Sharma, M. Stastna, C. Huang, M. Aniag, A. Aceves, JE. Van Eyk, RM. Mentzer, H. Piplani, AM. Andres, RA. Gottlieb

. 2021 ; 22 (16) : . [pub] 20210813

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025125

Grantová podpora
15SDG23230013 American Heart Association
P01-HL112730 NIH HHS - United States
R01-HL132075 NIH HHS - United States
R01-HL144509 NIH HHS - United States
RVO:68081715 Czech Academy of Sciences

Cardiovascular disease is the main cause of death worldwide, making it crucial to search for new therapies to mitigate major adverse cardiac events (MACEs) after a cardiac ischemic episode. Drugs in the class of the glucagon-like peptide-1 receptor agonists (GLP1Ra) have demonstrated benefits for heart function and reduced the incidence of MACE in patients with diabetes. Previously, we demonstrated that a short-acting GLP1Ra known as DMB (2-quinoxalinamine, 6,7-dichloro-N-[1,1-dimethylethyl]-3-[methylsulfonyl]-,6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline or compound 2, Sigma) also mitigates adverse postinfarction left ventricular remodeling and cardiac dysfunction in lean mice through activation of parkin-mediated mitophagy following infarction. Here, we combined proteomics with in silico analysis to characterize the range of effects of DMB in vivo throughout the course of early postinfarction remodeling. We demonstrate that the mitochondrion is a key target of DMB and mitochondrial respiration, oxidative phosphorylation and metabolic processes such as glycolysis and fatty acid beta-oxidation are the main biological processes being regulated by this compound in the heart. Moreover, the overexpression of proteins with hub properties identified by protein-protein interaction networks, such as Atp2a2, may also be important to the mechanism of action of DMB. Data are available via ProteomeXchange with identifier PXD027867.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025125
003      
CZ-PrNML
005      
20211026134110.0
007      
ta
008      
211013s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22168711 $2 doi
035    __
$a (PubMed)34445425
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a de Freitas Germano, Juliana $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
245    10
$a Proteomics of Mouse Heart Ventricles Reveals Mitochondria and Metabolism as Major Targets of a Post-Infarction Short-Acting GLP1Ra-Therapy / $c J. de Freitas Germano, A. Sharma, M. Stastna, C. Huang, M. Aniag, A. Aceves, JE. Van Eyk, RM. Mentzer, H. Piplani, AM. Andres, RA. Gottlieb
520    9_
$a Cardiovascular disease is the main cause of death worldwide, making it crucial to search for new therapies to mitigate major adverse cardiac events (MACEs) after a cardiac ischemic episode. Drugs in the class of the glucagon-like peptide-1 receptor agonists (GLP1Ra) have demonstrated benefits for heart function and reduced the incidence of MACE in patients with diabetes. Previously, we demonstrated that a short-acting GLP1Ra known as DMB (2-quinoxalinamine, 6,7-dichloro-N-[1,1-dimethylethyl]-3-[methylsulfonyl]-,6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline or compound 2, Sigma) also mitigates adverse postinfarction left ventricular remodeling and cardiac dysfunction in lean mice through activation of parkin-mediated mitophagy following infarction. Here, we combined proteomics with in silico analysis to characterize the range of effects of DMB in vivo throughout the course of early postinfarction remodeling. We demonstrate that the mitochondrion is a key target of DMB and mitochondrial respiration, oxidative phosphorylation and metabolic processes such as glycolysis and fatty acid beta-oxidation are the main biological processes being regulated by this compound in the heart. Moreover, the overexpression of proteins with hub properties identified by protein-protein interaction networks, such as Atp2a2, may also be important to the mechanism of action of DMB. Data are available via ProteomeXchange with identifier PXD027867.
650    _2
$a zvířata $7 D000818
650    _2
$a výpočetní biologie $7 D019295
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a receptor pro glukagonu podobný peptid 1 $x agonisté $7 D000067757
650    _2
$a glykolýza $7 D006019
650    _2
$a srdeční komory $x metabolismus $7 D006352
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a srdeční mitochondrie $x metabolismus $7 D008929
650    _2
$a oxidativní fosforylace $7 D010085
650    _2
$a mapy interakcí proteinů $7 D060066
650    _2
$a proteomika $x metody $7 D040901
650    _2
$a chinoxaliny $x aplikace a dávkování $x farmakologie $7 D011810
650    _2
$a sarkoplazmatická Ca2+-ATPáza $x metabolismus $7 D053498
650    _2
$a remodelace komor $x účinky léků $7 D020257
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sharma, Ankush $u Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway $u KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, 0318 Oslo, Norway
700    1_
$a Stastna, Miroslava $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA $u Institute of Analytical Chemistry of the Czech Academy of Sciences, 60200 Brno, Czech Republic
700    1_
$a Huang, Chengqun $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
700    1_
$a Aniag, Marianne $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
700    1_
$a Aceves, Angie $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
700    1_
$a Van Eyk, Jennifer E $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
700    1_
$a Mentzer, Robert M $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
700    1_
$a Piplani, Honit $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
700    1_
$a Andres, Allen M $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
700    1_
$a Gottlieb, Roberta A $u Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA 90048, USA
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 16 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34445425 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134116 $b ABA008
999    __
$a ok $b bmc $g 1714260 $s 1145632
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 16 $e 20210813 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 15SDG23230013 $p American Heart Association
GRA    __
$a P01-HL112730 $p NIH HHS $2 United States
GRA    __
$a R01-HL132075 $p NIH HHS $2 United States
GRA    __
$a R01-HL144509 $p NIH HHS $2 United States
GRA    __
$a RVO:68081715 $p Czech Academy of Sciences
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

    Možnosti archivace